Ainos, Inc. — 10-Q Summary
Entity note: The supplied filing is for Amarillo Biosciences, Inc., not Ainos, Inc. Confirm that this is the intended filing. It covers the quarter and nine months ended September 30, 2013; financial statements are unaudited.
Business context and financial results
Amarillo Biosciences focused on developing low-dose oral interferon and sought financing and pharmaceutical partners to advance clinical development and commercialization. Management reported that commercialization would require further development, testing, regulatory approval, and substantial capital.
| Metric | Three months ended September 30, 2013 | Nine months ended September 30, 2013 | Comparable 2012 period |
|---|---|---|---|
| Revenue | $0 | $0 | $50 and $530, respectively |
| Operating expenses | $84,452 | $408,031 | $131,635 and $435,362 |
| Operating loss | $84,452 | $408,031 | $131,605 and $435,044 |
| Net loss | $115,553 | $495,223 | $146,775 and $511,516 |
| Net loss applicable to common shareholders | $123,650 | $519,516 | $154,872 and $534,269 |
Gross profit was zero in 2013 because there were no sales. The filing reports no meaningful revenue base from which to assess operating margins.
Cash, liquidity, debt, and balance sheet
- At September 30, 2013, cash was $9,105, total current assets were $42,990, and total assets were $139,143.
- Current liabilities were $4,786,454, producing a working-capital deficit of $4,743,464. Stockholders’ deficit was $4,647,311; accumulated deficit was $37,348,770.
- Nine-month operating cash use was $474,912; investing cash use was $14,079, primarily patent expenditures; financing provided $490,835. Ending cash was $9,105, versus $302 at September 30, 2012.
- Related-party notes payable totaled $3,339,293, with $1,039,182 of accrued related-party interest. The company disclosed that two $1 million HBL notes were in repayment default, although HBL had not demanded payment. A $20,000 Wells Fargo credit line had $18,677 outstanding, included in accounts payable and accrued expenses.
- Management estimated a cash burn rate of approximately $50,000 per month and said liquidity and recurring losses raised substantial doubt about the company’s ability to continue as a going concern.
Changes versus prior periods
- Third-quarter operating expenses fell 36% year over year, primarily due to lower personnel costs; net loss declined 21%.
- For the nine months, R&D expense fell 57% to $105,450, while selling, general and administrative expense rose 58% to $302,581, reflecting higher travel, insurance, consulting, legal, patent, and professional fees. Operating loss declined 6% and net loss declined 3%.
- Interest expense for the nine months fell to $91,409 from $129,442. Derivative fair-value gains were $4,217, compared with $37,750 in 2012; the filing attributes the absence of a third-quarter 2013 derivative gain to the expiration of relevant warrants.
- No stock was sold in the first nine months of 2013. Common shares outstanding were reported as 73,291,008 at September 30, versus 73,554,897 at December 31, 2012.
Outlook, material events, and risks
- On October 31, 2013, after the reporting date, the company filed a voluntary Chapter 11 petition and operated as a debtor in possession. Management said continuation depended on court confirmation of a reorganization plan, creditor approval, recapitalization, and interim and permanent financing; failure could force the company to cease operations.
- The company reported receiving $142,000 from the Yang Group after September 30 through November 1 under its financing arrangements. A Yang Group secured revolving note allowed advances up to $300,000; $145,000 had been advanced by September 30. The filing also describes a separate $976,793 demand note and related-party advances.
- Management did not expect significant sales or royalty revenue in the next several years. It said the loss of its source of natural human interferon jeopardized the core technology and could lead to termination of distribution or licensing agreements. Finding a replacement supply was described as costly and time-consuming.
- The filing discusses clinical findings in influenza and hepatitis C but states that additional studies would be needed for further validation and that financing and interferon supply constraints impede progress. FDA approval remained necessary for the principal product.
- The filing identifies bankruptcy, financing, clinical and regulatory outcomes, intellectual-property protection, third-party supply and distribution, competition, and retention of key personnel as significant risks. Common stock began trading on the OTCQB under “AMARQ” on November 4, 2013; management cautioned that equity holders in Chapter 11 may recover little or nothing.
Important facts for investors to verify
- Whether the intended issuer is Amarillo Biosciences rather than Ainos, Inc.
- The Chapter 11 case’s current status, any confirmed reorganization plan, financing obtained, and expected treatment of equity and creditor claims.
- The amounts, priority, security, repayment status, and related-party nature of outstanding notes and accrued interest.
- Whether the company secured a replacement interferon supply and whether partner agreements remained in force.
- Current cash runway, actual operating burn, and any subsequent financing or material changes in share count.
- The clinical evidence, regulatory pathway, and funding required to advance oral interferon products.